Evidence map›Paper›PMID 40287727›Full record

ArticleJournal of nanobiotechnology2025

Hypoxia-responsive core-cross-linked supramolecular nanoprodrug based on dendritic drug-drug conjugates for synergetic anticancer therapy.

Yue Ding, Yu Xie, Liangshun Zheng, Mingguang Lin, Yihai Shi, Tingting Chen, Chang Du, Jin Ding, Beifang Ning

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Yue DingSchool of Chemistry and Chemical Engineering, Nantong University, Nantong, 226019, P. R. China. yueding@ntu.edu.cn.
Yu XieSchool of Chemistry and Chemical Engineering, Nantong University, Nantong, 226019, P. R. China.
Liangshun ZhengSchool of Chemistry and Chemical Engineering, Nantong University, Nantong, 226019, P. R. China.
Mingguang LinDepartment of Gastroenterology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Yihai ShiDepartment of Gastroenterology, Shanghai Pudong New Area Gongli Hospital, Shanghai, 200135, China.
Tingting ChenSchool of Chemistry and Chemical Engineering, Nantong University, Nantong, 226019, P. R. China.
Chang DuClinical Cancer Institute, Center for Translational Medicine, Naval Medical University, Shanghai, China. duchang19901030@163.com.
Jin DingClinical Cancer Institute, Center for Translational Medicine, Naval Medical University, Shanghai, China. dingjin1103@163.com.
Beifang NingDepartment of Gastroenterology, Changzheng Hospital, Naval Medical University, Shanghai, China. ningbeifang@163.com.

Funding

Innovation Program of Shanghai Municipal Education Commission 20230548Medical Discipline Construction Project of Pudong Health Committee of Shanghai PWYgf2021-08Natural Science Foundation of Jiangsu Province BK20240950Project of Shanghai Municipal Health Commission 202240347Science and Technology Project of Nantong City MS2023040Shanghai Key Laboratory of Cell Engineering 14DZ2272300
6 · The paper itself

Abstract

backgroundRecently, the strategy of self-assembling dendritic drug-drug conjugates into supramolecular nanoprodrug was widely explored in biomedical applications. Herein, we construct a hypoxia-responsive core-cross-linked supramolecular nanoprodrug (CSN-IR806/CB) based on a dendritic drug-drug conjugate.

methodsWe prepared a hypoxia-responsive dendritic drug-drug conjugates IR806-(Azo-CB)

resultsThe near-infrared (NIR) light irradiation of the CSN-IR806/CB treated tumor cells induced IR806-mediated PDT and PTT, and aggravated hypoxia, which triggered the disassembly of CSN-IR806/CB and the subsequent release of activated CB for synergetic cancer cell killing.

conclusionsThe CSN-IR806/CB can realize a synergistic triple therapeutic effect of photothermal therapy (PTT), photodynamic therapy (PDT), and chemotherapy (CT; i.e., PTT-PDT-CT).

Indexed as

Antineoplastic AgentsDendrimersNanoparticlesProdrugsbeta-CyclodextrinsCell Line, TumorCell SurvivalHumansNeoplasmsPhotochemotherapyPolyethylene GlycolsAntineoplastic Agentsbeta-CyclodextrinsDendrimersPolyethylene GlycolsProdrugsCombination therapyDendritic drug-drug conjugateHost-guest complexationHypoxiaSupramolecular nanoprodrug

Identifiers

PMID40287727
PMCPMC12032639

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.